文献速递肿瘤 PET/CT核素与放射性配体治疗

CAIX靶向放射性示踪剂用于透明细胞肾细胞癌诊断及VEGFR-TKI疗效监测

CAIX-targeted radiotracer for diagnosis and monitoring VEGFR-TKI response in clear cell renal cell carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-09

本研究设计三种靶向CAIX的放射性示踪剂,在体外和体内评估,并在8例ccRCC患者中比较[68Ga]Ga-NOTA-FZCI-3与[18F]-FDG PET/CT的诊断效能。结果显示[68Ga]Ga-NOTA-FZCI-3在肾脏病灶SUVmax和转移灶肿瘤/肌肉比方面优于[18F]-FDG,且在OS-RC-2模型中可监测VEGFR-TKI疗效。

要点

  • [68Ga]Ga-NOTA-FZCI-3在ccRCC患者中肾脏病灶SUVmax中位13.10,高于[18F]-FDG的3.10(P=0.04)。
  • 转移灶肿瘤/肌肉比[68Ga]Ga-NOTA-FZCI-3为9.25±5.10,优于[18F]-FDG的3.64±2.11(P=0.004)。
  • [68Ga]Ga-NOTA-FZCI-3 PET/CT在VEGFR-TKI治疗中显示肿瘤摄取明显下降,可监测疗效。

核心结论

  • [68Ga]Ga-NOTA-FZCI-3是改善ccRCC诊断、分期及VEGFR-TKI疗效监测的有前景的放射性示踪剂。

研究设计与样本

  • 研究开发三种靶向CAIX的新型放射性示踪剂,并进行体外和体内评估。
  • 研究纳入8例ccRCC患者,均接受配对的[68Ga]Ga-NOTA-FZCI-3 PET/CT和[18F]-FDG PET/CT,比较两种示踪剂的诊断效能。
  • 在OS-RC-2模型上进行使用[68Ga]Ga-NOTA-FZCI-3的VEGFR-TKI疗效监测实验。

主要发现

  • 三种示踪剂显示不同的肝/肾积聚,与血浆蛋白结合能力等因素相关。
  • [68Ga]Ga-NOTA-FZCI-3在患者中主要经肝胆系统清除。
  • 在8例ccRCC患者的前瞻性队列中,[68Ga]Ga-NOTA-FZCI-3的肾脏病灶SUVmax中位13.10 vs. 3.10(n=4;P=0.04),转移灶肿瘤/肌肉比9.25±5.10 vs. 3.64±2.11(n=16;P=0.004),均优于[18F]-FDG。
  • 在VEGFR-TKI疗效监测实验中,[68Ga]Ga-NOTA-FZCI-3显示治疗期间肿瘤放射性示踪剂摄取明显下降。
  • 治疗组VEGFR-AKT-mTOR通路抑制和CAIX下调证实[68Ga]Ga-NOTA-FZCI-3 PET/CT是监测肾细胞癌TKI疗效的可行策略。

关键数值与推荐

  • 肾脏病灶SUVmax中位13.10 vs. 3.10(n=4;P=0.04)。
  • 转移灶肿瘤/肌肉比9.25±5.10 vs. 3.64±2.11(n=16;P=0.004)。

临床怎么用

  • [68Ga]Ga-NOTA-FZCI-3 PET/CT可用于ccRCC的诊断、分期及VEGFR-TKI疗效监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Carbonic anhydrase IX (CAIX) represents a promising target for molecular imaging of clear cell renal cell carcinoma (ccRCC). We designed three radiotracers targeting CAIX to improve the diagnostic value of imaging by increasing tumor uptake and the liver excretion pathway. We also aimed to demonstrate the feasibility of applying small-molecule radiotracers in VEGFR-TKI efficacy monitoring in renal cancer. METHODS: This study developed three novel CAIX-targeting radiotracers, which were evaluated in vitro and in vivo; The study also included 8 patients with ccRCC, all of whom had paired [68Ga]Ga-NOTA-FZCI-3 PET/CT and [18F]-FDG PET/CT. The diagnostic efficacies of these two PET tracers were compared. Moreover, VEGFR-TKI efficacy monitoring experiments using [68Ga]Ga-NOTA-FZCI-3 was conducted on OS-RC-2 models. RESULTS: Three radiotracers showed that different liver/renal accumulations were better correlated with factors including distinct plasma protein binding abilities. [68Ga]Ga-NOTA-FZCI-3, primarily cleared through the hepatobiliary system in patients, demonstrated a higher SUVmax of renal lesions (median, 13.10 vs. 3.10, n = 4; *P = 0.04) and superior tumor-to-muscle ratio of metastatic lesions (9.25 ± 5.10 vs.3.64 ± 2.11, n = 16; **P = 0.004) to [18F]-FDG in a prospective cohort with 8 ccRCC patients. In VEGFR-TKI efficacy monitoring experiments, [68Ga]Ga-NOTA-FZCI-3 showed markedly decreased tumor radiotracer uptake throughout treatment. Moreover, VEGFR-AKT-mTOR pathway inhibition and CAIX downregulation in the treatment group confirmed that [68Ga]Ga-NOTA-FZCI-3 PET/CT is a viable strategy for monitoring TKI efficacy in renal cell cancer. CONCLUSION: [68Ga]Ga-NOTA-FZCI-3 is a promising radiotracer for improving diagnosis, staging, and VEGFR-TKI efficacy monitoring in ccRCC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Guo H, Xu X, Liu C, et al. CAIX-targeted radiotracer for diagnosis and monitoring VEGFR-TKI response in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2026. PMID: 41656421. doi:10.1007/s00259-026-07783-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。